Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation
Jacksonville, Fla., Rochester, Minn.
Trial status: Open for Enrollment
Why is this study being done?
A randomized, controlled trial designed to demonstrate the safety and effectiveness of the experimental device to deliver pulmonary vein isolation as a treatment for symptomatic atrial fibrillation.
Who is eligible to participate?
- 18 to 75 years.
- paroxysmal atrial fibrillation
- failure of at least one AAD
- overall good health as established by multiple criteria